All In Biotech

Drug Trial Radar · NCT04315792

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Last checked: Nov 19, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Aug 3, 2020

Primary completion

Jan 25, 2021

Study completion Aug 25, 2021

Sponsor

Lead sponsor
Jina Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Novum Pharmaceutical Research Services; Lambda Therapeutic Research Ltd.
First posted
Mar 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the study population. As endoxifen represents a totally new class of drugs in the treatment of the bipolar disorder, it is essential to compare the drug against placebo to rule out the psychological influence upon study results. More so given the risks to patients and their communities from a medication whose efficacy has not been thoroughly evaluated against a placebo control. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products.

Conditions

  • Bipolar I Disorder

Interventions

  • EndoxifenDrug

    Administration of Endoxifen for 3 weeks

  • Placebo oral tabletDrug

    Administration of Placebo for 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy and establish superiority of endoxifen 8 mg against placebo in Bipolar I Disorder patients (Mean change in total YMRS score)Time frame: 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 16420 NW 59 Avenue

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.